Statistics

Total Visits

Views
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r9

Select a period of time:

Number of views in the range

Views
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r3

Views

Views
November 20230
December 20231
January 20240
February 20241
March 20240
April 20240
May 20241
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States3
 

Top cities views

Views
Ashburn1